<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77242">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01911845</url>
  </required_header>
  <id_info>
    <org_study_id>M14-103</org_study_id>
    <nct_id>NCT01911845</nct_id>
  </id_info>
  <brief_title>An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine</brief_title>
  <official_title>An Open-label, Single-Arm, Phase 2 Study to Evaluate the Combination of ABT-450/r/ABT-267 and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Hepatitis C Virus (HCV) Infection Taking Methadone or Buprenorphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 and
      ABT-333 coadministered with RBV in HCV genotype 1 adults taking Methadone or Buprenorphine.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with virologic failure during treatment</measure>
    <time_frame>up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid greater than the lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with relapse post treatment</measure>
    <time_frame>48 weeks after all subjects complete 12 week treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid greater than the lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>One visit per subject between treatment week 2 and treatment week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine AUC, Cmax, Tmax and C trough for at least 20 subjects participating in intensive PK sampling</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HCV</condition>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450/r/ABT-267</intervention_name>
    <description>tablet</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333</intervention_name>
    <description>tablet</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribovirin (RBV)</intervention_name>
    <description>tablet</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HCV-infection prior to study enrollment.

          -  Screening laboratory result indicating HCV genotype 1-infection.

          -  Subject must be treatment naive or previous pegylated interferon/ribavirin treatment
             experienced.

          -  Subjects must be on a stable opioid replacement therapy of methadone or buprenorphine
             Â± naloxone for at least 6 months prior to screening.

        Exclusion Criteria:

          -  Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human
             Immunodeficiency virus antibody (HIV Ab) at screening.

          -  Prior therapy with direct acting antiviral agents for the treatment of HCV, including
             telaprevir and boceprevir.

          -  Females who are pregnant or plan to become pregnant, or breastfeeding, or males whose
             partners are pregnant or planning to become pregnant within 7 months (or per local
             RBV label) after their last dose of study drug.

          -  Any current or past clinical evidence of cirrhosis such as ascites or esophageal
             varices, or prior biopsy showing cirrhosis, e.g., a Metavir Score of &gt;3 or Ishak
             score of &gt; 4.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan  Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100498</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100755</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100522</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100495</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100756</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100521</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100497</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100496</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>May 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV Genotype 1</keyword>
  <keyword>Hepatitis Genotype 1</keyword>
  <keyword>Interferon Free</keyword>
  <keyword>methadone</keyword>
  <keyword>HCV</keyword>
  <keyword>Buprenorphine</keyword>
  <keyword>Hepatitis C</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
